Security
CLIMB BIO INC · ELYM
ELYMOTCCommon stockHistorical · closed Oct 2, 2024CIK 1768446Updated Oct 29, 2026
Name history
Eliem Therapeutics, Inc. · through Sep 20, 2024
Current security for this SEC filerCLYM · NASDAQ
ELYM price & chart
Historical security
This listing closed Oct 2, 2024. Live provider charts are shown only for current listings.
Current security: CLYM
About the company
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G - filed by Flynn James E regarding Climb Bio, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 182,304,000Source | 222,199,000Source | 246,294,000Source | 192,386,000Source | 226,018,000Source | 152,372,000Source | 200,740,000Source | 109,334,000Source | 167,744,000Source | 217,187,000Source | 110,469,000Source | 134,992,000Source |
| Property, Plant and Equipment, NetUSD | 318,000Source | — | 695,000Source | 314,000Source | — | 250,000Source | — | — | 288,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 25,803,000Source | 146,175,000Source | 44,107,000Source | 22,682,000Source | 223,140,000Source | 8,356,000Source | 29,020,000Source | 105,031,000Source | 35,685,000Source | 87,229,000Source | 93,112,000Source | 43,585,000Source |
| Assets, CurrentUSD | 90,964,000Source | 197,611,000Source | 186,636,000Source | 87,384,000Source | 225,997,000Source | 113,404,000Source | 100,280,000Source | 109,223,000Source | 105,849,000Source | 154,872,000Source | 110,255,000Source | 134,393,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,063,000Source | 4,260,000Source | 3,513,000Source | 2,681,000Source | 2,857,000Source | 3,840,000Source | 2,218,000Source | 4,192,000Source | 4,769,000Source | 3,953,000Source | 3,457,000Source | 10,827,000Source |
| Operating Lease, Right-of-Use AssetUSD | 562,000Source | 12,000Source | 1,216,000Source | 618,000Source | 21,000Source | 447,000Source | 451,000Source | 111,000Source | 505,000Source | 490,000Source | 199,000Source | 471,000Source |
| Other Assets, NoncurrentUSD | 1,530,000Source | 0Source | 1,649,000Source | 1,368,000Source | 0Source | 1,530,000Source | 226,000Source | 0Source | 1,530,000Source | 215,000Source | 15,000Source | 128,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,301,000Source | 3,423,000Source | 6,747,000Source | 6,622,000Source | 3,741,000Source | 4,287,000Source | 7,355,000Source | 2,950,000Source | 7,269,000Source | 5,306,000Source | 2,870,000Source | 6,277,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 6,000Source | 7,000Source | 7,000Source | 5,000Source | 7,000Source | 3,000Source | 5,000Source | 7,000Source | 3,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -272,211,000Source | -221,460,000Source | -316,947,000Source | -259,323,000Source | -212,565,000Source | -303,449,000Source | -250,657,000Source | -157,676,000Source | -289,727,000Source | -229,876,000Source | -155,979,000Source | -120,860,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 469,000Source | 201,000Source | -67,000Source | 318,000Source | 0Source | 157,000Source | 286,000Source | 0Source | 435,000Source | 23,000Source | -2,000Source | -358,000Source |
| Stockholders' Equity Attributable to ParentUSD | 177,003,000Source | 218,776,000Source | 239,547,000Source | 185,764,000Source | 222,277,000Source | 148,085,000Source | 193,385,000Source | 106,384,000Source | 160,475,000Source | 211,881,000Source | 107,599,000Source | 128,715,000Source |
| Additional Paid in Capital, Common StockUSD | 448,738,000Source | 440,028,000Source | 556,555,000Source | 444,762,000Source | 434,835,000Source | 451,372,000Source | 443,749,000Source | 264,057,000Source | 449,762,000Source | 441,727,000Source | 263,577,000Source | 249,930,000Source |
| Liabilities and EquityUSD | 182,304,000Source | 222,199,000Source | 246,294,000Source | 192,386,000Source | 226,018,000Source | 152,372,000Source | 200,740,000Source | 109,334,000Source | 167,744,000Source | 217,187,000Source | 110,469,000Source | 134,992,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,949,000Source | 3,423,000Source | 5,934,000Source | 6,205,000Source | 3,741,000Source | 4,071,000Source | 7,036,000Source | 2,950,000Source | 6,984,000Source | 4,931,000Source | 2,833,000Source | 6,097,000Source |
| Operating Lease, Liability, CurrentUSD | 228,000Source | 58,000Source | 501,000Source | 222,000Source | 100,000Source | 263,000Source | 155,000Source | 225,000Source | 256,000Source | 157,000Source | 334,000Source | 300,000Source |
| Accounts Payable, CurrentUSD | 477,000Source | 291,000Source | 1,133,000Source | 946,000Source | 509,000Source | 860,000Source | 777,000Source | 85,000Source | 2,269,000Source | 705,000Source | 66,000Source | 750,000Source |
| Operating Lease, Liability, NoncurrentUSD | 352,000Source | 0Source | 813,000Source | 417,000Source | 0Source | 216,000Source | 319,000Source | 0Source | 285,000Source | 375,000Source | 15,000Source | 180,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 22,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 3,045,000Source | — | — | 2,950,000Source | — | 6,104,000Source | 2,640,000Source | — | 4,069,000Source | 2,433,000Source | 5,047,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 160,700,000Source | — | — | 123,600,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -13,722,000Source | -20,781,000Source | -59,851,000Source | -73,897,000Source | -35,119,000Source | -45,244,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 38,000Source | 0Source | 97,000Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,605,000Source | 2,022,000Source | 8,054,000Source | 5,557,000Source | 12,806,000Source | 6,991,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,409,000Source | 72,000Source | 1,564,000Source | -963,000Source | -686,000Source | -653,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -14,379,000Source | -15,434,000Source | -54,356,000Source | -15,562,000Source | -20,599,000Source | -37,369,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -12,955,000Source | -42,751,000Source | 2,833,000Source | -121,092,000Source | 68,981,000Source | 34,440,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 186,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,000Source | 0Source | -21,000Source | 130,729,000Source | 841,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -27,329,000Source | -58,209,000Source | -51,544,000Source | -5,883,000Source | 49,527,000Source | -3,337,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 25,803,000Source | 146,175,000Source | 44,250,000Source | 22,682,000Source | 8,356,000Source | 29,020,000Source | 35,685,000Source | 87,229,000Source | 93,112,000Source | 43,585,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,976,000Source | 2,922,000Source | 1,481,000Source | 1,013,000Source | 1,605,000Source | 2,022,000Source | 8,054,000Source | 5,557,000Source | 12,806,000Source | 6,991,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 160,700,000Source | — | — | 123,600,000Source |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | 0Source | 0Source | — | — | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -33,000Source | 52,000Source | 6,000Source | -162,000Source | -25,000Source | -50,000Source | -291,000Source | 42,000Source | 304,000Source | -408,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | — | — | — | -1,484,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -21,000Source | -24,000Source | -18,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,819,000Source | 5,492,000Source | 5,645,000Source | 4,102,000Source | 5,838,000Source | 5,691,000Source | 21,170,000Source | 16,025,000Source | 24,864,000Source | 18,921,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 2,037,000Source | 2,785,000Source | 1,855,000Source | 2,173,000Source | 1,514,000Source | 2,287,000Source | 8,323,000Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 151,000Source | 201,000Source | -224,000Source | 32,000Source | -278,000Source | 263,000Source | 412,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,888,000Source | -8,895,000Source | -13,498,000Source | -8,666,000Source | -13,722,000Source | -20,781,000Source | -59,851,000Source | -73,897,000Source | -35,119,000Source | -45,244,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -45,244,000Source |
| Operating ExpensesUSD | — | — | 14,892,000Source | 11,732,000Source | 15,359,000Source | 10,677,000Source | 15,211,000Source | 23,018,000Source | 67,883,000Source | 82,020,000Source | 40,275,000Source | 45,135,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 58,000Source | 39,000Source | 201,000Source | 220,000Source | 405,000Source | 443,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 2,837,000Source | — | — | — | 2,237,000Source | 8,032,000Source | 8,123,000Source | 5,156,000Source | -109,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 1,375,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | — | 10,979,000Source | 841,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,000Source | 0Source | 65,000Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | 201,000Source | — | — | — | 263,000Source | — | 25,000Source | 356,000Source | -235,000Source |
| Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -14,892,000Source | -11,732,000Source | -15,359,000Source | -10,677,000Source | -15,211,000Source | -23,018,000Source | -67,883,000Source | -82,020,000Source | -40,275,000Source | -45,135,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 2,837,000Source | — | — | — | 2,237,000Source | 8,032,000Source | 8,123,000Source | 5,156,000Source | -109,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,888,000Source | -8,895,000Source | -13,498,000Source | -8,666,000Source | -13,722,000Source | -20,781,000Source | -59,851,000Source | -73,897,000Source | -35,119,000Source | -45,244,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.13Source | -0.18Source | -0.13Source | -0.2Source | -0.31Source | -0.88Source | -1.53Source | -1.3Source | -1.72Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.13Source | -0.18Source | -0.13Source | -0.2Source | -0.31Source | -0.88Source | -1.53Source | -1.3Source | -1.72Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 68,003,248Source | 67,014,183Source | 76,154,071Source | 67,585,121Source | 68,207,313Source | 67,462,450Source | 67,812,145Source | 48,163,301Source | 26,987,122Source | 26,311,554Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 68,003,248Source | 67,014,183Source | 76,154,071Source | 67,585,121Source | 68,207,313Source | 67,462,450Source | 67,812,145Source | 48,163,301Source | 26,987,122Source | 26,311,554Source |
| Additional Financial Items | ||||||||||||
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -33,000Source | 52,000Source | 6,000Source | -162,000Source | -25,000Source | -50,000Source | -291,000Source | 42,000Source | 304,000Source | -408,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | — | — | — | -1,484,000Source |
| General and Administrative ExpenseUSD | — | — | 5,819,000Source | 5,492,000Source | 5,645,000Source | 4,102,000Source | 5,838,000Source | 5,691,000Source | 21,170,000Source | 16,025,000Source | 24,864,000Source | 18,921,000Source |
| Interest Income, OperatingUSD | — | — | — | — | — | — | — | — | — | 8,132,000Source | — | — |
| Investment Income, InterestUSD | — | — | 2,037,000Source | 2,785,000Source | 1,855,000Source | 2,173,000Source | 1,514,000Source | 2,287,000Source | 8,323,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -45,244,000Source |
| Operating ExpensesUSD | — | — | 14,892,000Source | 11,732,000Source | 15,359,000Source | 10,677,000Source | 15,211,000Source | 23,018,000Source | 67,883,000Source | 82,020,000Source | 40,275,000Source | 45,135,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 58,000Source | 39,000Source | 201,000Source | 220,000Source | 405,000Source | 443,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 1,375,000Source |
| Research and Development ExpenseUSD | — | — | 9,073,000Source | 6,240,000Source | 9,714,000Source | 6,575,000Source | 9,373,000Source | 17,327,000Source | 46,713,000Source | 14,176,000Source | 15,411,000Source | 26,214,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | 2,233,000Source | — | — | — | — | — | 2,253,000Source | 8,983,000Source | — |
| Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Operating Income | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-296346
Filing attachments
clym-ex99_1.htm · 8-K · 2026-10-26
Exhibit 99.1 Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 mg and 600 mg doses have been generally well-tolerated Separate MCD case study described three-year steroid-free remission following budoprutug treatm…
Read attachment ↗clym-ex99_2.htm · 8-K · 2026-10-26
Corporate Presentation OCTOBER 2026 Forward Looking Statements This presentation contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; the anticipated timelines for enrolling patients in Climb Bio’s ongoing and planned clinical trials; plans for the development strategy for budoprutug …
Read attachment ↗clym-ex99_1.htm · 8-K · 2026-10-23
Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first half of 2027 Global Phase 3 trial expected to initiate in 2027 WELLESLEY HILLS, USA, and BEIJING, China, Octobe…
Read attachment ↗d97033dex991.htm · 8-K · 2026-09-03
EX-99.1 2 d97033dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-…
Read attachment ↗d97033dex992.htm · 8-K · 2026-09-03
EX-99.2 3 d97033dex992.htm EX-99.2 EX-99.2 R&D Spotlight: CLYM116 Initial Phase 1 Results September 3, 2026 Exhibit 99.2 Forward Looking Statements This presentation contains “forward-looking statements”, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of CLYM116; the anticipated timelines for reporting clinical data from Climb Bio’s ongoin…
Read attachment ↗clym-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 clym-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data expected from pMN, ITP, and SLE studies in Q4 2026 Financing extends cash runway into the second half of…
Read attachment ↗